

92. The fusion protein of claim 62, wherein the stress protein is hsp71.

93. The fusion protein of claim 54, wherein the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophilin, an Hsp20-30, C1pP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase.

94. The method of claim 64, wherein the immune response is a cell mediated immune response.

95. The method of claim 95, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

96. The method of claim 95, wherein the cell mediated immune response is a class I-restricted T cell response.

97. The method of claim 95, wherein the cell mediated immune response is a class II-restricted T cell response.

98. A fusion protein comprising a human papillomavirus (HPV) antigen, or an antigenic portion thereof, and a stress protein or a portion thereof, wherein the fusion protein induces an immune response to the HPV antigen in a mammal to whom the fusion protein is administered.

99. The fusion protein of claim 99, wherein the HPV antigen is an E6 protein.

100. The fusion protein of claim 99, wherein the HPV antigen is an E7 protein.

101. The fusion protein of claim 99, wherein the HPV antigen includes a CTL epitope.

102. The fusion protein of claim 102, wherein the CTL epitope is a class I-restricted T cell epitope.

103
104. The fusion protein of claim 102, wherein the CTL epitope is a class II-restricted T cell epitope.

105. The fusion protein of claim 99, wherein the stress protein is a bacterial stress protein.

106. The fusion protein of claim 99, wherein the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophilin, an Hsp20-30, C1pP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase.

107. The fusion protein of claim 99, wherein the stress protein is a mycobacterial stress protein.

108. The fusion protein of claim 107, wherein the stress protein is hsp65.

109. The fusion protein of claim 107, wherein the stress protein is hsp71.

110. The fusion protein of claim 99, wherein the immune response is a cell mediated immune response.

111. The fusion protein of claim 110, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

112. The fusion protein of claim 110, wherein the cell mediated immune response is a class-I restricted T cell response.

113. The fusion protein of claim 110, wherein the cell mediated immune response is a class II-restricted T cell response.

114. A composition comprising the fusion protein of claim 99 and a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

115. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim 99 to the mammal in an amount effective to induce an immune response against the antigen.

116. The method of claim 115, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

117. The method of claim 115, wherein the immune response is a cell mediated immune response.

118. The method of claim 117, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

119. The method of claim 117, wherein the cell mediated immune response is a class I-restricted T cell response.

120. The method of claim 117, wherein the cell mediated immune response is a class II-restricted T cell response.

121. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim 100 to the mammal in an amount effective to induce an immune response against the antigen.

122. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim 101 to the mammal in an amount effective to induce an immune response against the antigen.

123. The fusion protein of claim 101, wherein the stress protein is mycobacterial Hsp65.

124. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim 123 to the mammal in an amount effective to induce an immune response against the antigen.--